Login to Your Account


Wednesday, February 3, 2016

Spero Therapeutics LLC, of Cambridge, Mass., said existing series A investors Atlas Venture, SR One, MRL Ventures, Lundbeckfond Ventures, the Kraft Group and Partners Innovation Fund will provide $30 million in preferred B funding.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription